Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: Amneal Pharmaceuticals LLC
Current Parent Company: Amneal Pharmaceuticals
Penalty: $400,000
Year: 2019
Date: September 10, 2019
Offense Group: competition-related offenses
Primary Offense: price-fixing or anti-competitive practices
Violation Description: Amneal Pharmaceuticals, Sun Pharmaceuticals Industries Ltd, and Upsher-Smith Laboratories LLC together agreed to pay $1.2 million to end-payor plaintiffs to settle litigation alleging they entered into an anti-competitive deal to block a generic version of the Alzheimer's drug Namenda. Court documents did not indicate how much each company would pay. Here we assume they each paid an equal share of the total.
Level of Government: federal
Action Type: private litigation
Court: Southern District of New York
Civil or Criminal Case: civil
Case ID: 1:15cv6549
Case Name: In re Namenda Indirect Purchaser Antitrust Litigation
Private Lawsuit Resolution Type: settlement
HQ Country of Current Parent: USA
HQ State of Current Parent: New Jersey
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
Link to PACER Case Docket (must be logged in): (click here)
Link to Archived Court Document:  subscribe to see this data field
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.